A study has recently found that patients with type 1 diabetes taking canagliflozin (or Invokana) were at a greater risk of ketoacidosis than patients taking a placebo. The drug is an SGLT-2 inhibitor, and in May 2015, the FDA warned that it and other similar drugs are associated with ketoacidosis. A recent study from the University of Southern California further explored these issues.
The study examined a group of 117 diabetic patients, and at the end of an 18-week trial, it was found that 5.1% of the group taking 100 mg of canagliflozin experienced diabetic ketoacidosis and 9.4% of the group receiving 300 mg doses also experienced the condition. No cases of ketoacidosis were experienced by patients in the placebo group.
These findings were published in Diabetes Care on March 17, 2016.